Cucurbitacin-D-induced CDK1 mRNA up-regulation causes proliferation arrest of a Non-Small Cell Lung Carcinoma Cell line (NSCLC-N6)

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 4797-4806

  Jacquot, Catherine ^a   Rousseau, Benedicte ^a   Carbonnelle, Delphine ^a   Chinou, Ioanna ^b   Malleter, Marine ^a   Tomasoni, Christophe ^a   Roussakis, Christos ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis; CDK1; Cucurbitacin D; Ecbalium elaterium; G1 cell cycle arrest; Gene expression; Lung cancer; NSCLC N6

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; CUCURBITACIN; CUCURBITACIN D; CYCLIN DEPENDENT KINASE 1; MESSENGER RNA; UNCLASSIFIED DRUG; CDK1; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL LINE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SEQUENCE ANALYSIS; UPREGULATION; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECT; ECBALIUM ELATERIUM; GENE EXPRESSION REGULATION; GENETICS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NSCLC-N6; TUMOR CELL LINE;

APOPTOSIS; CDK1; CUCURBITACIN D; ECBALIUM ELATERIUM; G1 CELL CYCLE ARREST; GENE EXPRESSION; LUNG CANCER; NSCLC-N6;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CDC2 PROTEIN KINASE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; RNA, MESSENGER; TRITERPENES; UP-REGULATION;

EID: 84908680723     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. De Castria TB, da Silva EMK, Gois AFT and Riera R: Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 8: CD009256, 2013.
2. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncol Williston Park N 18(7 Suppl 4): 3-9, 2004.
3. Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson D, Miller A, Graziano S, Perry M, Saville W, Chahinian P, Weeks J, Holland J and Green M: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol Off J Am Soc Clin Oncol 23(1): 190-196, 2005.
4. Favoni RE and Alama A: Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. Drug Discov Today 18(1-2): 11-24, 2013.
5. Yared JA and Tkaczuk KHR: Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 6: 371-384, 2012.
6. Onrubia M, Cusidó RM, Ramirez K, Hernandez V, Moyano E, Bonfill M and Palazon J: Bioprocessing of plant in vitro systems for the mass production of pharmaceutically important metabolites: paclitaxel and its derivatives. Curr Med Chem 20(7): 880-891, 2013.
7. Seifert K and Elgamal MH: New cucurbitacin glucosides from Ecballium elaterium L. Pharm 32(10): 605-606, 1977.
8. Yesilada E, Tanaka S, Sezik E and Tabata M: Isolation of an anti-inflammatory principle from the fruit juice of Ecballium elaterium. J Nat Prod 51(3): 504-508, 1988.
9. Bohlooli S, Jafari N and Jahed S: Cytotoxic effect of freeze-dried extract of Ecballium elaterium fruit on gastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cell lines. J Gastrointest Cancer 43(4): 579-583, 2012.
10. Adwan G, Salameh Y and Adwan K: Effect of ethanolic extract of Ecballium elaterium against Staphylococcus aureus and Candida albicans. Asian Pac J Trop Biomed 1(6): 456-460, 2011.
11. Attard E, Brincat MP and Cuschieri A: Immunomodulatory activity of cucurbitacin E isolated from Ecballium elaterium. Fitoterapia 76(5): 439-441, 2005.
12. Fuller RW, Cardellina JH 2nd, Cragg GM and Boyd MR: Cucurbitacins: Differential cytotoxicity, dereplication and first isolation from Gonystylus keithii. J Nat Prod 57(10): 1442-1445, 1994.
13. Ishii T, Kira N, Yoshida T and Narahara H: Cucurbitacin D induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial and ovarian cancer cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med 34(1): 285-291, 2013.
14. Ding N, Yamashita U, Matsuoka H, Sugiura T, Tsukada J, Noguchi J and Yoshida Y: Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia. Cancer 117(12): 2735-2746, 2011.
15. Takahashi N, Yoshida Y, Sugiura T, Matsuno K, Fujino A and Yamashita U: Cucurbitacin D isolated from Trichosanthes kirilowii induces apoptosis in human hepatocellular carcinoma cells in vitro. Int Immunopharmacol 9(4): 508-513, 2009.
16. Roussakis C, Gratas C, Audouin AF, Le Boterff J, Dabouis C, Andre MJ, Moyon E, Vo NH, Pradal G and Verbist JF: Study of in vitro drug sensitivity on a newly established cell line from a primary bronchial epidermoid carcinoma of human origin (NSCLCN6). Anticancer Res 11(6): 2239-2244, 1991.
17. Chinou I, Liolios C, Moreau D and Roussakis C: Cytotoxic activity of Origanum dictamnus. Fitoterapia 78(5): 342-344, 2007.
18. Kofinas C, Chinou L, Loukis A, Harvala C, Roussakis C, Maillard C and Hostettmann K: Cytotoxic coumarins from the aerial parts of Tordylium apulum and their effects on a non-small-cell bronchial carcinoma cell line. Planta Med 64(2): 174-176, 1998.
19. Mihopoulos N, Vagias C, Chinou I, Roussakis C, Scoullos M, Harvala C and Roussi V: Antibacterial and cytotoxic natural and synthesized hydroquinones from sponge Ircinia spinosula. Z Für Naturforschung C J Biosci 54(5-6): 417-423, 1999.
20. Riou D, Colliec-Jouault S, Pinczon du Sel D, Bosch S, Siavoshian S, Le Bert V, Tomasoni C, Sinquin C, Durand P and Roussakis C: Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Anticancer Res 16(3A): 1213-1218, 1996.
21. Riou D, Roussakis C, Biard JF and Verbist JF. Comparative study of the antitumor activity of bistramides A, D and K against a non-small cell broncho-pulmonary carcinoma. Anticancer Res 13(6A): 2331-2334, 1993.
22. Bourgougnon N, Roussakis C, Kornprobst JM and Lahaye M: Effects in vitro of sulfated polysaccharide from Schizymenia dubyi (Rhodophyta, Gigartinales) on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Cancer Lett 85(1): 87-92, 1994.
23. Bergé JP, Bourgougnon N, Carbonnelle D, LE Bert V, Tomasoni C, Durand P and Roussakis C: Antiproliferative effects of an organic extract from the marine diatom Skeletonema costatum (Grev.) Cleve. Against a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Anticancer Res 17(3C): 2115-2120, 1997.
24. Jacquot C, Moreau D, Tomasoni C, Juge M, Coiffard L, Roussis V and Roussakis C: Proliferation arrest in G1 phase of a nonsmall cell lung cancer cell line (NSCLC-N6) treated by an original compound methyl-4-methoxy-3-(3-methyl-2-butanoyl) benzoate (VT1) independently of the p53/p21 cascade. Int J Oncol 23(2): 495-501, 2003.
25. Sunday ME. Differential display RT-PCR for identifying novel gene expression in the lung. Am J Physiol 269(3 Pt 1): L273-284, 1995.
26. Adam PJ. The Use of Differential mRNA Display (DDRTPCR) to Identify Genes Differentially Expressed in Normal and Diseased Vascular Cells. Methods Mol Med 30: 99-110, 1999.
27. Chomczynski P and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1): 156-159, 1987.
28. Chomczynski P and Sacchi N: The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1(2): 581-585, 2006.
29. Frohman MA, Dush MK and Martin GR. Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci USA 85(23): 8998-9002, 1988.
30. Scotto-Lavino E, Du G and Frohman MA. 5' end cDNA amplification using classic RACE. Nat Protoc 1(6): 2555-2562, 2006.
31. Taylor MF. Antisense oligonucleotides for target validation and gene function determination. IDrugs Investig Drugs J 2(8): 777-781, 1999.
32. Agrawal S and Kandimalla ER. Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today 6(2): 72-81, 2000.
33. Roussakis C, Robillard N, Riou D, Biard JF, Pradal G, Piloquet P, Debitus C and Verbist JF: Effects of bistramide A on a non-small-cell bronchial carcinoma line. Cancer Chemother Pharmacol 28( 4): 283-292, 1991.
34. Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28(33): 2925-2939, 2009.
35. Lee DH, Iwanski GB and Thoennissen NH: Cucurbitacin: ancient compound shedding new light on cancer treatment. ScientificWorldJournal 10: 413-418, 2010.
36. Kim SR, Seo HS, Choi H-S, Cho SG, Kim YK, Hong EH, Shin YC and Ko SG: Trichosanthes kirilowii Ethanol Extract and Cucurbitacin D Inhibit Cell Growth and Induce Apoptosis through Inhibition of STAT3 Activity in Breast Cancer Cells. Evid-Based Complement Altern Med ECAM 2013: 975350, 2013.
37. Liscia E, Riou D, Slavoshian S, Bosh S, Lebert V, Tomasoni C, Dabouis G, Biard JF and Roussakis C: Terminal differentiation in a non-small-cell bronchopulmonary carcinoma correlates with increased expression of p53. Anticancer Res 16(3A): 1209-1212, 1996.
38. Siavoshian S, Jacquot C, Biard JF, Briand G and Roussakis C: Subtractive hybridization and differential screening identified two genes differentially expressed after induction of in vitro (atypical) terminal differentiation in the NSCLC-N6 cell line by a marine substance (bistramide K). Anticancer Res 19(6B): 5361-5365, 1999.
39. Carbonnelle D, Jacquot C, Lanco X, Le Dez G, Tomasoni C, Braind G, Tsotinis A, Calogeropou T and Roussakis C: Upregulation of a novel mRNA (NY-CO-1) involved in the methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate (VT1)-induced proliferation arrest of a non-small-cell lung carcinoma cell line (NSCLC-N6). Int J Cancer 92(3): 388-397, 2001.
40. Jacquot C, Lanco X, Carbonnelle D, Sevestre O, Tomasoni C, Briand G, Juget M, Roussis V and Roussakis C: Effect of four genes (ALDH1, NRF1, JAM and KBL) on proliferation arrest in a non-small cell bronchopulmonary cancer line. Anticancer Res 22(4): 2229-2235, 2002.
41. Jacquot C, Carbonnelle D, Tomasoni C, Papaconstadinou A, Roussis V and Roussakis C: Identification of a novel putative non-coding RNA involved in proliferation arrest of a non-small cell lung carcinoma cell line treated with an original chemical substance, methyl-4-methoxy-3-(3-methyl-2-butanoyl) benzoate. Int J Oncol 25(2): 519-527, 2004.
42. Lee MG and Nurse P: Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327( 6117): 31-35, 1987.
43. Graña X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11(2): 211-219, 1995.
44. Corlu A and Loyer P: Regulation of the g1/s transition in hepatocytes: involvement of the cyclin-dependent kinase cdk1 in the DNA replication. Int J Hepatol 2012: 68932, 2012.
45. Diallo A and Prigent C. [The serine/threonine kinases that control cell cycle progression as therapeutic targets]. Bull Cancer (Paris) 98(11): 1335-1345, 2011.
46. Welch PJ and Wang JY: Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle. Proc Natl Acad Sci USA 89(7): 3093-3097, 1992.
47. Uhlmann F, Bouchoux C and López-Avilés S: A quantitative model for cyclin-dependent kinase control of the cell cycle: revisited. Philos Trans R Soc Lond B Biol Sci 366(1584): 3572-3583, 2011.
48. Enserink JM and Kolodner RD: An overview of Cdk1-controlled targets and processes. Cell Div 5: 11, 2010.
49. Fisher D, Krasinska L, Coudreuse D and Novák B: Phosphorylation network dynamics in the control of cell cycle transitions. J Cell Sci 125(Pt 20): 4703-4711, 2012.
50. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH and Shin DY: p53 negatively regulates cdc2 transcription via the CCAATbinding NF-Y transcription factor. J Biol Chem 274(42): 29677-29682, 1999.
51. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW and Greenberg AH: Premature p34cdc2 activation required for apoptosis. Science 263(5150): 1143-1145, 1994.
52. Castedo M, Perfettini J-L, Roumier T and Kroemer G: Cyclindependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9(12): 1287-1293, 2002.
53. Chadebech P, Truchet I, Brichese L and Valette A: Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int J Cancer 87(6): 779-786, 2000.